Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux

Zanubrutinib (ZAN) is a Bruton’s tyrosine kinase inhibitor recently approved for the treatment of some non-Hodgkin lymphomas. In clinical trials, ZAN is often combined with standard anthracycline (ANT) chemotherapy. Although ANTs are generally effective, drug resistance is a crucial obstacle that le...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Lucie Čermáková, Jakub Hofman, Lenka Laštovičková, Lucie Havlíčková, Ivona Špringrová, Eva Novotná, Vladimír Wsól
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2022-09-01
Цуврал:	Pharmaceutics
Нөхцлүүд:	zanubrutinib anthracycline drug resistance aldo-keto reductase 1C3 ABC drug efflux transporter
Онлайн хандалт:	https://www.mdpi.com/1999-4923/14/10/1994
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!